XML 41 R34.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Oct. 29, 2024
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Summary Of Significant Accounting Policies [Line Items]                    
Cash, cash equivalents and restricted cash, maturity period               three months or less    
Net income (loss)   $ 76,971 $ (44,907) $ (23,631) $ (9,906) $ (65,760) $ (10,772) $ 8,433 $ (86,438)  
Net income (losses) excluding gain of change in fair value of warrant   (19,500)           (43,400)    
Cash and cash equivalents and short-term investments   78,200           78,200    
Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds   96,439     443     51,829 (55,738)  
Working capital   69,000           69,000    
Accumulated deficit   $ (310,969)     $ (289,303)     $ (310,969) $ (289,303) $ (319,402)
Common stock, shares issued   41,183,102           41,183,102   24,213,130
Common stock, par value   $ 0.001           $ 0.001   $ 0.001
Accounting Standards Update 2023-09 [Member]                    
Summary Of Significant Accounting Policies [Line Items]                    
Change in accounting principle, accounting standards update, adopted   true           true    
Accounting Standards Update 2023-07 [Member]                    
Summary Of Significant Accounting Policies [Line Items]                    
Change in accounting principle, accounting standards update, adopted   true           true    
Anelixis Therapeutics, LLC and Otic Pharma, Ltd.                    
Summary Of Significant Accounting Policies [Line Items]                    
Ownership interest percentage               100.00%    
Leerink Partners LLC [Member] | Subsequent event | Underwriting agreement [Member]                    
Summary Of Significant Accounting Policies [Line Items]                    
Proceeds From Issuance Offering $ 85,000                  
Net proceeds after deducting offering costs $ 79,500                  
Warrants [Member] | Leerink Partners LLC [Member] | Subsequent event | Underwriting agreement [Member]                    
Summary Of Significant Accounting Policies [Line Items]                    
Warrant exercise price $ 3.649                  
Common Stock [Member] | Leerink Partners LLC [Member] | Subsequent event | Underwriting agreement [Member]                    
Summary Of Significant Accounting Policies [Line Items]                    
Common stock, shares issued 18,356,173                  
Common stock, par value $ 0.001                  
Offering price common stock 3.65                  
Warrant exercise price $ 0.001                  
Common stock warrants exercisable 4,931,507                  
Otic Pharma, Inc. [Member]                    
Summary Of Significant Accounting Policies [Line Items]                    
Ownership interest percentage               100.00%